Chart, page-3971

IMO the upcoming data points is not probably but rather now is pivotal to BP engagement if it confirms + 12 months duration of effect on our primary end points. Nothing like it is available on the market and it will be years before other treatment options can show an equivalent or any meaningful duration (including stem cell, HA, PRP).

Ironically, those that have used it or administered iPPS know the pain benefits typically exceed well past 12 months and out past 2 years.

The consultants we've engaged to facilitate structured regional deals are world class senior executives from ex-BP, who can hone in on what is critical to BP. They may help surprise the market in a rather dramatic fashion sooner than most at present think.

I'm increasingly positive on the above but also based on the overwhelming negative psychology of the crowd.

Either way we all get to decide for ourselves post the release of this latest data point and likely direction PAR takes from here.